LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 117

Search options

  1. Article: Cancer Screening and Prevention in Crohn's Disease Patients.

    Lashner, Bret

    Gastroenterology & hepatology

    2017  Volume 2, Issue 10, Page(s) 726–727

    Language English
    Publishing date 2017-03-06
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2386402-3
    ISSN 1554-7914
    ISSN 1554-7914
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Dual Targeted Therapy for the Management of Inflammatory Bowel Disease.

    Haider, Mahnur / Lashner, Bret

    Journal of clinical gastroenterology

    2021  Volume 55, Issue 8, Page(s) 661–666

    Abstract: The burden of inflammatory bowel disease (IBD) is increasing globally and imposes a high morbidity in patients with IBD. Advances have been made in medical management of IBD with the advent of novel therapies such as the biologics and small molecule ... ...

    Abstract The burden of inflammatory bowel disease (IBD) is increasing globally and imposes a high morbidity in patients with IBD. Advances have been made in medical management of IBD with the advent of novel therapies such as the biologics and small molecule drugs (SMDs). However, response to these medications is limited; with only 40% of patients achieving clinical remission at 1 year with a biologic. Hence, medical management of IBD is a rapidly evolving paradigm in which not only are new medications being developed but understanding how, when and in whom to use them is evolving. Dual targeted therapy (DTT), which is the combination of biologics and/or SMDs is an attractive concept as it is theoretically a potent and multidimensional anti-inflammatory treatment strategy. In this review, we present the published literature on the use of DTT and highlight its utility in clinical practice. The majority of studies on DTT are case reports and case series on the combination of dual biologic therapy. From the limited evidence available in patients with IBD, dual biologic therapy may be a safe option for patients with refractory IBD who have failed multiple biologic therapies and to manage extraintestinal manifestation of IBD. There are a handful of reports of combination therapy with a biologic and a SMD in patients with IBD. Further studies and randomized control trials are required to comprehensivretain hereely evaluate the safety and efficacy of DTT in IBD.
    MeSH term(s) Anti-Inflammatory Agents/adverse effects ; Colitis ; Humans ; Inflammatory Bowel Diseases/drug therapy
    Chemical Substances Anti-Inflammatory Agents
    Language English
    Publishing date 2021-07-07
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 448460-5
    ISSN 1539-2031 ; 0192-0790
    ISSN (online) 1539-2031
    ISSN 0192-0790
    DOI 10.1097/MCG.0000000000001583
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Conflicts of Interest in Clinical Practice Guidelines.

    Lashner, Bret A / Cominelli, Fabio

    Inflammatory bowel diseases

    2018  Volume 25, Issue 4, Page(s) 646

    MeSH term(s) Conflict of Interest ; Humans ; Inflammatory Bowel Diseases ; Societies, Medical
    Language English
    Publishing date 2018-10-08
    Publishing country England
    Document type Editorial ; Comment
    ZDB-ID 1340971-2
    ISSN 1536-4844 ; 1078-0998
    ISSN (online) 1536-4844
    ISSN 1078-0998
    DOI 10.1093/ibd/izy317
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Gastrointestinal manifestations of COVID-19.

    El Ouali, Sara / Achkar, Jean-Paul / Lashner, Bret / Regueiro, Miguel

    Cleveland Clinic journal of medicine

    2021  

    Abstract: Gastrointestinal (GI) symptoms are seen in patients with COVID-19. The prevalence could be as high as 50%, but most studies show ranges from 16% to 33%. Presenting with GI symptoms increases the risk of testing positive for SARs-CoV-2. Approximately 50% ... ...

    Abstract Gastrointestinal (GI) symptoms are seen in patients with COVID-19. The prevalence could be as high as 50%, but most studies show ranges from 16% to 33%. Presenting with GI symptoms increases the risk of testing positive for SARs-CoV-2. Approximately 50% of patients with COVID-19 have detectable virus in their stool. Having GI symptoms has been associated with more severe disease. Management of GI symptoms is mainly supportive. Healthcare providers should be aware of the GI manifestations of COVID-19 and perform SARS-CoV-2 testing for patients presenting with digestive changes, especially in those with respiratory symptoms.
    Keywords covid19
    Language English
    Publishing date 2021-02-17
    Publishing country United States
    Document type Journal Article
    ZDB-ID 639116-3
    ISSN 1939-2869 ; 0891-1150
    ISSN (online) 1939-2869
    ISSN 0891-1150
    DOI 10.3949/ccjm.87a.ccc049
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Reducing the Spread of Internet Misinformation in IBD: Ethics and Responsibility.

    Kurowski, Jacob A / Bewtra, Meenakshi / Kodish, Eric / Lashner, Bret

    Inflammatory bowel diseases

    2021  Volume 27, Issue 6, Page(s) 960–962

    MeSH term(s) Communication ; Disinformation ; Ethics, Medical ; Humans ; Inflammatory Bowel Diseases ; Internet
    Language English
    Publishing date 2021-01-04
    Publishing country England
    Document type Journal Article
    ZDB-ID 1340971-2
    ISSN 1536-4844 ; 1078-0998
    ISSN (online) 1536-4844
    ISSN 1078-0998
    DOI 10.1093/ibd/izaa335
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Utility of Biomarkers in the Management of Inflammatory Bowel Disease.

    Kochhar, Gursimran / Lashner, Bret

    Current treatment options in gastroenterology

    2017  Volume 15, Issue 1, Page(s) 105–115

    Abstract: Opinion statement: Inflammatory bowel disease (IBD) is comprised of complex clinical and pathological conditions. It runs a chronic course, and proper management requires constant monitoring of disease activity. Recent evidence suggests that subjective ... ...

    Abstract Opinion statement: Inflammatory bowel disease (IBD) is comprised of complex clinical and pathological conditions. It runs a chronic course, and proper management requires constant monitoring of disease activity. Recent evidence suggests that subjective patient scores have a poor correlation with disease activity. Endoscopy remains the gold standard for diagnosing and monitoring disease activity. As healthcare is moving towards less costly and less invasive treatments, the need for biomarkers in the management of IBD is evident. Over the last decade, several biomarkers have been found, which may correct the discrepancy between subjective patient scores and the need for endoscopy.
    Language English
    Publishing date 2017-01-30
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2057334-0
    ISSN 1534-309X ; 1092-8472
    ISSN (online) 1534-309X
    ISSN 1092-8472
    DOI 10.1007/s11938-017-0129-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Informed Consent in IBD Trials: Where We Are and Where We Need to Go.

    Kurin, Michael / Katz, Jeffry / Kodish, Eric / Lashner, Bret

    Inflammatory bowel diseases

    2019  Volume 25, Issue 7, Page(s) 1115–1119

    Abstract: Patient enrollment is increasingly recognized as a major limiting factor to inflammatory bowel disease (IBD) clinical trial completion. Many IBD trials will fail to enroll enough patients to adequately power their study. This has led to a renewed ... ...

    Abstract Patient enrollment is increasingly recognized as a major limiting factor to inflammatory bowel disease (IBD) clinical trial completion. Many IBD trials will fail to enroll enough patients to adequately power their study. This has led to a renewed multifaceted effort to encourage more patients to enroll in clinical trials. Although this is of clear importance, it is also important to ensure that all efforts to enroll patients in clinical trials do not compromise the quality and validity of the patient's/study participant's informed consent. Informed consent has 4 components: disclosure, voluntariness, understanding, and capacity. The application of informed consent to IBD clinical trials for biologic agents has not been previously studied. Yet the nature of clinical trials for biologics in IBD creates certain challenges to properly fulfilling the requirements of informed consent in the recruitment process that should be examined. In the following commentary, the components of informed consent are reviewed, challenges to their fulfillment in IBD trials are reviewed, and practical advice is offered.
    MeSH term(s) Biomedical Research/standards ; Clinical Trials as Topic/methods ; Clinical Trials as Topic/standards ; Comprehension ; Disclosure ; Humans ; Inflammatory Bowel Diseases/therapy ; Informed Consent/statistics & numerical data ; Research Subjects
    Language English
    Publishing date 2019-04-15
    Publishing country England
    Document type Editorial
    ZDB-ID 1340971-2
    ISSN 1536-4844 ; 1078-0998
    ISSN (online) 1536-4844
    ISSN 1078-0998
    DOI 10.1093/ibd/izz067
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Correspondence on: Methodological Standards When Reporting From National Databases.

    Naseem, Khadija / Sohail, Abdullah / Nguyen, Vu Quang / Khan, Ahmad / Cooper, Gregory / Lashner, Bret / Katz, Jeffry / Cominelli, Fabio / Regueiro, Miguel / Mansoor, Emad

    Inflammatory bowel diseases

    2024  

    Language English
    Publishing date 2024-05-02
    Publishing country England
    Document type Editorial ; Comment
    ZDB-ID 1340971-2
    ISSN 1536-4844 ; 1078-0998
    ISSN (online) 1536-4844
    ISSN 1078-0998
    DOI 10.1093/ibd/izae072
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Surgical risks in patients on inflammatory bowel disease medications.

    Lashner, Bret A

    Gastroenterology & hepatology

    2011  Volume 7, Issue 4, Page(s) 246–247

    Language English
    Publishing date 2011-07-28
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2386402-3
    ISSN 1554-7914
    ISSN 1554-7914
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Our Vision for the Future of Inflammatory Bowel Diseases: Research, Innovations, and Controversies.

    Lashner, Bret / Cominelli, Fabio

    Inflammatory bowel diseases

    2016  Volume 23, Issue 1, Page(s) 1

    Language English
    Publishing date 2016-12-20
    Publishing country England
    Document type Editorial
    ZDB-ID 1340971-2
    ISSN 1536-4844 ; 1078-0998
    ISSN (online) 1536-4844
    ISSN 1078-0998
    DOI 10.1097/MIB.0000000000001018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top